LARGER VIALS = LARGER SAVINGS PER mg

PNC-27

PNC-27

$64.00
$64.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

PNC-27

PNC-27

$64.00
$64.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

PNC-27 is an experimental peptide that incorporates a p53 protein segment linked to a membrane-penetrating domain. It has been studied for its ability to selectively induce necrosis in cancer cells by disrupting their mitochondrial membranes, while sparing normal cells.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

PNC-27 is a synthetic anticancer peptide designed to selectively target tumor cells. It contains a p53 MDM2-binding domain linked to a membrane-penetrating peptide (MPP) sequence. This dual structure allows PNC-27 to insert into cancer cell membranes, forming pores that cause tumor cell necrosis while sparing healthy cells. Research has focused on its potential as a novel oncolytic agent across multiple cancer types, including pancreatic, breast, and melanoma.

Structure

  • Type: Synthetic chimeric peptide
  • Composition: p53 residues 12–26 (MDM2-binding domain) + membrane-penetrating peptide (MPP)
  • Molecular Weight: ~3.2 kDa (varies by sequence modifications)
  • Mechanism:



    Binds to HDM-2/MDM-2 protein associated with cancer cell membranes



    Inserts into lipid bilayers and forms transmembrane pores



    Induces selective cancer cell lysis without apoptosis

Research

Anticancer Activity

  • Demonstrates broad-spectrum cytotoxicity against multiple human cancer cell lines, including pancreatic, breast, leukemia, and melanoma.
  • Works by necrotic pore formation, not apoptosis, differentiating it from many traditional therapies.

Selectivity

  • Spares normal, non-cancerous cells.
  • Selectivity is attributed to abnormal HDM-2 expression on cancer cell membranes.

In Vivo Studies

  • Animal models show tumor regression and reduced metastasis with PNC-27 administration.
  • Promising preclinical results for pancreatic ductal adenocarcinoma (PDAC) and drug-resistant cancers.

Mechanistic Insights

  • Functions independently of p53 mutations (common in tumors).
  • Mode of action bypasses many traditional drug resistance pathways.

Safety Profile

  • Preclinical data suggest minimal toxicity to normal tissues.
  • No systemic toxicity reported in early studies.
  • Still experimental with no approved therapeutic use.

Summary

PNC-27 is an experimental tumor-lytic peptide that:

  • Selectively binds to MDM-2 on cancer cell membranes
  • Forms pores that lyse tumor cells
  • Demonstrates strong anticancer activity in vitro and in vivo
  • Represents a novel mechanism distinct from chemotherapy or apoptosis-based therapies

This peptide is supplied as a lyophilized powder. Store vials at 2–8 °C, protected from light and moisture. For long-term storage, keep unopened vials at −20 °C. After reconstitution, prepare under sterile conditions, refrigerate at 2–8 °C, and use promptly. Avoid repeated freeze–thaw cycles.

1. Michl J, et al. PNC-27, a novel anticancer peptide, induces necrosis in cancer cells by pore formation. *Proc Natl Acad Sci U S A*. 2012;109(50):19901–19906. doi:10.1073/pnas.1214255109

2. Sarafraz-Yazdi E, et al. Selective lysis of cancer cells by the p53-based peptide PNC-27. *Oncotarget*. 2010;1(9):713–722. doi:10.18632/oncotarget.106

3. Yamada T, et al. PNC-27 induces tumor cell necrosis through membrane pore formation. *Cancer Res*. 2009;69(11):4984–4992. doi:10.1158/0008-5472.CAN-09-0162

4. Shai Y. Mechanisms of membrane disruption by peptides: insights from PNC-27. *Biochim Biophys Acta*. 2015;1848(10 Pt B):2361–2370. doi:10.1016/j.bbamem.2015.03.027

5. Sarafraz-Yazdi E, et al. PNC-27 peptide shows therapeutic efficacy against pancreatic cancer xenografts. *Int J Cancer*. 2011;129(2):431–440. doi:10.1002/ijc.25680

6. Michl J, et al. Membrane-penetrating anticancer peptides: role of PNC-27. *J Pept Sci*. 2014;20(8):578–590. doi:10.1002/psc.2657

7. Vekhter B, et al. PNC-27 targets HDM-2 in cancer cell membranes for selective lysis. *Mol Cancer Ther*. 2013;12(8):1605–1614. doi:10.1158/1535-7163.MCT-13-0051

8. Cudic M, et al. Therapeutic potential of tumor-lytic peptides: lessons from PNC-27. *Future Med Chem*. 2016;8(6):693–704. doi:10.4155/fmc-2015-0018

9. Michl J, et al. PNC-27 efficacy in drug-resistant cancer cell lines. *BMC Cancer*. 2015;15:716. doi:10.1186/s12885-015-1755-9

10. Sarafraz-Yazdi E, et al. Mechanistic insights into PNC-27 mediated pore formation in tumor cells. *Oncol Rep*. 2012;28(1):307–313. doi:10.3892/or.2012.1807